Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Calendar quarter Q2 2026Earnings call Jul 29, 2026 · most recent call
BSX’s newest analyzed quarter is part of Tellvest Pro: its score, breakdown, narrative and analyst Q&A. Every prior quarter is free.
Sources. Scores: Boston Scientific’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: BSX daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
All prior quarters are free. How to browse earnings-call scores without Pro. How to read a company earnings-call score.
The breakdown for this quarter is part of Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $4.56B | +22.4% | $0.38 | +11.3% | 58.6% | 12.9% | 12.4% | $1.16B |
| FY2025 Q1 | $4.66B | +20.9% | $0.45 | +35.1% | 63.3% | 19.2% | 14.5% | $354M |
| FY2025 Q2 | $5.06B | +22.8% | $0.53 | +142.8% | 67.7% | 16.2% | 15.7% | $1.10B |
| FY2025 Q3 | $5.07B | +20.3% | $0.50 | +58.6% | 69.9% | 20.7% | 14.9% | $1.16B |
| FY2025 Q4 | $5.29B | +15.9% | $0.45 | +18.5% | 74.5% | 22.8% | 12.6% | $1.01B |
| FY2026 Q1 | $5.20B | +11.6% | $0.90 | +99.4% | 69.4% | 20.6% | 25.7% | $171M |
| FY2026 Q2Selected | $5.44B | +7.5% | $0.61 | +15.1% | 70.7% | 21.6% | 16.7% | — |
Management-stated figures from BSX’s newest call are part of Tellvest Pro.
On October 7, 2026, Boston Scientific announced that Joe Fitzgerald, Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer effective January 1, 2027. Mr. Fitzgerald, 63, joined the company in 1990 and has held his current role since May 2022. As COO he will receive a $1,050,000 base salary, a 110% annual bonus target and a 2027 equity award with a $7,000,000 grant date fair value.
On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation that he decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific, effective January 1, 2027. He is expected to remain with the company as a senior advisor through February 26, 2027, at his current annual base salary of $780,000, prorated through the retirement date.
On August 25, 2026, Boston Scientific identified a cybersecurity incident affecting certain IT systems that resulted in a global disruption to operations. The Company activated incident response protocols and engaged third-party experts to contain and investigate the threat. The incident has caused, and is expected to continue causing, disruptions and limited access to systems and applications supporting operations, including the ability to process and ship customer orders.
What each event means for BSX’s sentiment score is part of Tellvest Pro.